BMGLBasel Medical Group Ltd Ordinary Shares
The schedule
- Sun29Nov
Management is slated to unveil its strategic roadmap detailing network expansions, provider partnerships, and updated reimbursement contract terms for the upcoming year.
- Fri26Mar
- Wed31Mar
The year-end financial report will serve as the ultimate verdict on BMGL's multi-quarter turnaround, requiring definitive proof of sustainable cash flows.
- Fri25Jun
- Fri24Sep
- Fri24Dec
Past
- Mon9Nov
Actual outcome: Bear · $0.69 at outcome
BMGL experienced a sharp decline due to a significant earnings miss and downward guidance, which triggered a sell-off. The company reported lower-than-expected revenue and profit, with management cutting growth expectations for the near term, leading to a loss of investor confidence. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -64.4% from 2026-11-09 to 2026-11-10 (~4.8σ vs typical 1d vol). Target evaluation date 2026-11-14 (not yet reached as of 2026-11-10). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-11-11: -64.3% from 2026-11-10 (~3.8σ). Target evaluation date 2026-11-14 (not yet reached as of 2026-11-11).
BMGL experienced a sharp decline due to a significant earnings miss and downward guidance, which triggered a sell-off. The company reported lower-than-expected revenue and profit, with management cutting growth expectations for the near term, leading to a loss of investor confidence. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -64.4% from 2026-11-09 to 2026-11-10 (~4.8σ vs typical 1d vol). Target evaluation date 2026-11-14 (not yet reached as of 2026-11-10). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-11-11: -64.3% from 2026-11-10 (~3.8σ). Target evaluation date 2026-11-14 (not yet reached as of 2026-11-11).
- Fri25Sep
Actual outcome: Bear · $4.42 at outcome
BMGL reported a Q1 2026 earnings miss and provided weak guidance, which pressured the stock. The closing price on the outcome date of $4.42 fell materially below the bear floor of $3.50, reflecting investor concerns over the company's financial performance and outlook. The stock's decline was driven by the disappointing results and lack of positive catalysts to offset the negative sentiment.
BMGL's mandatory Q1 2026 earnings release will be a pivotal test of its fundamental viability and ability to preserve margins amid shifting healthcare policies under President Trump.
- Sat15Aug
Actual outcome: Bear · $5.50 at outcome
The stock closed at $5.50, falling materially from the event date, which aligns with the bear case. The event, a potential equity financing or strategic capital raise, likely raised concerns about dilution and financial pressure, leading to a sell-off. The price action suggests investor sentiment turned negative, moving below the bear floor and away from the bull target.
With cash dwindling to just $1.3M against an operating cash burn of $1.6M, BMGL is under intense pressure to secure funding before its next reporting cycle.
- Tue30Jun
Actual outcome: Bull · $5.62 at outcome
Basel Medical Group's Q2 2026 business update revealed better-than-expected growth in covered lives and favorable medical loss ratio trends. This confirmation that the company's healthcare services are successfully scaling toward profitability satisfied investor expectations, keeping the stock elevated well above the $0.80 bull target.
Q2 2026 will likely be the first period where Basel Medical Group Ltd Ordinary Shares provides a more complete view of its healthcare services and plan membership metrics. With limited historical financials and a negative DCF value versus the current $0.55 share price, the street will focus on basic operating KPIs such as covered lives, premium growth, and medical loss ratio trends to gauge whether the business can scale toward profitability.